Table 2.
Radiologic and biological characteristics of the COVID-19 study patients.
| PE patients (n = 59) |
CTPA controls (n = 118) |
CT controls (n = 118) |
OR (95% CI)a | OR (95% CI)b | |
|---|---|---|---|---|---|
| Radiologic characteristic | |||||
| Findings of COVID-19 on the first chest CT performed | |||||
| Non suggestive | 4 (6.8) | 11 (9.3) | 7 (5.9) | ref | ref |
| Indeterminate | 10 (16.9) | 40 (33.9) | 47 (39.8) | 0.79 (0.21–2.95) | 0.30 (0.07–1.33) |
| Highly suggestive | 45 (76.3) | 67 (56.8) | 64 (54.3) | 3.33 (0.83–13.34) | 1.41 (0.30–6.54) |
| Extent of lung damage on the first chest CT performed | |||||
| <10% (limited) | 9 (15.2) | 19 (16.1) | 29 (24.6) | ref | ref |
| 10–50% (mild or moderate) | 23 (39.0) | 66 (55.9) | 70 (59.3) | 0.78 (0.29–2.14) | 1.07 (0.44–2.58) |
| >50% (severe or diffuse) | 27 (45.8) | 33 (28.0) | 19 (16.1) | 1.82 (0.63–5.23) | 3.90 (1.54–9.94) |
| Location of PE | |||||
| Pulmonary trunk | 12 (20.0) | – | – | – | – |
| Lobar artery | 15 (25.5) | – | – | – | – |
| Segmental artery | 24 (41.0) | – | – | – | – |
| Sub–segmental artery | 8 (13.5) | – | – | – | – |
| Biological characteristic | |||||
| D–dimersc (ng/mL) | 2605 (1436–7333) | 1237 (885–2075) | – | 5.11 (1.90–13.76) | – |
| Fibrinogend (g/L) | 6.6 (4.6–7.7) | 5.6 (4.9–7.0) | 5.45 (4.7–6.58) | 1.59 (0.71–3.55) | 2.20 (0.87–5.57) |
| CRPd (mg/L) | 136 (56–244) | 100 (30–158) | 88 (25–131) | 1.66 (0.84–3.27) | 3.36 (1.58–7.14) |
| Hemoglobine (g/dL) | 13.2 (11.9–14.2) | 13.3 (11.8–14.4) | 13.3 (12.3–14.5) | 0.70 (0.35–1.39) | 0.76 (0.40–1.43) |
| Platelet counte (G/L) | 227 (175–310) | 213 (148–288) | 201 (160–257) | 1.27 (0.65–2.48) | 1.36 (0.69–2.68) |
| Lymphocyte counte (M/L) | 895 (697–1342) | 860 (597–1242) | 865 (662–1220) | 1.55 (0.80–2.99) | 1.46 (0.67–3.16) |
| Creatininee (μmol/L) | 75 (60–90) | 77 (61–99) | 76 (61–94) | 0.77 (0.40–1.48) | 0.86 (0.42–1.75) |
| ASATe (IU/L) | 49 (33–79) | 48 (33–71) | 40 (28–57) | 1.15 (0.58–2.28) | 1.71 (0.86–3.41) |
| ALATe (IU/L) | 31 (22–59) | 30 (18–60) | 27 (17–49) | 1.20 (0.58–2.46) | 1.42 (0.68–2.99) |
Continuous parameters are reported as median (IQR) and data expressed as n (%). All percentages were calculated for available data for each variable.
a
PE patients versus CTPA controls.
b
PE patients versus CT controls.
c
Before CTPA assessment.
d
Higher level during hospitalization.
e
level at admission PE = pulmonary embolism; CTPA = computed tomography pulmonary angiogram; CT = unenhanced computed tomography; OR = odds ratio.